TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15300807
Drug: Serum PSA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PSA < 3 ng/ml
Study: 15300807
Drug: Serum PSA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PSA 3.0-3.9 ng/ml with benign digital rectal examination or free total PSA ratio > or = 0.16
Study: 8208391
Drug: Phentolamine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (35 mg) after saline infusion
Study: 8208391
Drug: Phenylephrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (500 micrograms) after saline infusion
Study: 2146057
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg every 8 hours)
Study: 2592580
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg every 12 hours)
Study: 30048414
Drug: Simulated sunlight
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated sunlight (1.3× standard erythemal dose in T‐shirt and shorts, three times per week for 4 wk and then once per week for 8 wk)
Study: 30048414
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (1000 IU·d for 4 wk and then 400 IU·d for 8 wk)
Study: 18683001
Drug: SDA-SBO (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDA-SBO (24 ml/day providing approximately 3.7 g SDA)
Study: 18683001
Drug: EPA (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (approximately 1 g/day)
Study: 7554393
Drug: IL-6 administered
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 administered by daily subcutaneous injection for 7 days at a dose level of 1, 3, or 10 micrograms/kg/day
Study: 2254511
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CB)
Study: 2254511
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control (WL) after treatment
Study: 2254511
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CB) at 10-week follow-up
Study: 7437255
Drug: Oxyfedrine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyfedrine (maximum dose 32 mg three times daily)
Study: 7437255
Drug: Propranolol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (maximum dose 120 mg three times daily)
Study: 17158441
Drug: Policosanol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol (20 mg)
Study: 2824365
Drug: Lithium countertransport
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium countertransport in hypertensive adults treated with antihypertensive medications
Study: 26507862
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg of rhBMP‐7 (Osigraft OP1) on a type I collagen carrier
Study: 22933541
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 10 μg/d
Study: 22933541
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 30 μg/d
Study: 22933541
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 40 μg/d
Study: 22933541
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 μg/d)
Study: 22933541
Drug: Control (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (30 μg/d)
Study: 22933541
Drug: Control (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (40 μg/d)
Study: 15722809
Drug: Daily pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pain duration
Study: 15722809
Drug: Daily mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mean VAS scores
Study: 11973381
Drug: Composite solution
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite solution I (amphipathic lipids)
Study: 11973381
Drug: Composite solution
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite solution II (amphipathic lipids)
Study: 8133112
Drug: Indirect immunofluorescent
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect immunofluorescent antibody (IFA) test for detection of Babesia microti antibody
Study: 797057
Drug: Dental procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dental procedures (extraction, filling therapy, prosthodontic procedures)
Study: 28445659
Drug: Adalimumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (20 mg or 40 mg according to body weight, administered subcutaneously every 2 weeks)
Study: 25537159
Drug: Afatinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (50 mg daily)
Study: 25537159
Drug: Lapatinib (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1500 mg daily)
Study: 25537159
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg loading dose, then 2 mg/kg/week)
Study: 19556536
Drug: Erythropoietin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin at any dose
Study: 17492951
Drug: Intravenous FFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous FFA infusion (intralipid/heparin infusion 4 h)
Study: 17492951
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (0.5 mg i.v.)
Study: 17492951
Drug: GHR blockade
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHR blockade (pegvisomant, 30 mg s.c.)
Study: 15352967
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propacetamol (2 g) and Diclofenac (75 mg)
Study: 1089446
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg daily
Study: 1089446
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg three times a week
Study: 30949710
Drug: Oral Δ9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Δ9‐tetrahydrocannabinol (THC)
Study: 24262217
Drug: Periodic Presumptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodic Presumptive Treatment (PPT)
Study: 17532774
Drug: RinsEndo-system; 5‐mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: RinsEndo-system; 5‐mL NaOCl, 50 s
Study: 17532774
Drug: Flushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flushing with a syringe; 5‐mL NaOCl, 1 min
Study: 11952508
Drug: IVAA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVAA 500 mg twice weekly for 8 weeks
Study: 11952508
Drug: IVAA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVAA 500 mg/week for 8 weeks (Group 1)
Study: 11952508
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Group 2)
Study: 11952508
Drug: Initial phase
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial phase IVAA treatment
Study: 266313
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy consisting of cytarabine and 6-thioguanine for two days each month
Study: 21150914
Drug: Intravenous THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous THC (1.25 mg)
Study: 15499961
Drug: Prediction rule
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction rule based on nine independent risk factors (gender, birthweight, educational level of the father, S. pneumoniae, cerebrospinal fluid leukocyte count, delay between admission and start of antibiotics, dexamethasone use, seizures treated with anticonvulsive therapy, prolonged fever)
Study: 11180763
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (neoadjuvant chemotherapy)
Study: 9131311
Drug: Furosemide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1.0 mg/kg/day)
Study: 9131311
Drug: Furosemide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1.0 mg/kg/day) plus Metolazone (0.2 mg/kg/day)
Study: 8482455
Drug: Albendazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (10 mg.kg‐1.day‐1 for 8 weeks)
Study: 8482455
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of percutaneous drainage and albendazole
Study: 3436158
Drug: 2.4 mega
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mega units procaine penicillin plus 1 g probenacid
Study: 25483417
Drug: Single loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single loading dose only
Study: 22317882
Drug: Hyoscine N-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butylbromide (1 mL, 20 mg IV)
Study: 22834281
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl solution)
Study: 20047622
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM)-based therapy
Study: 17207103
Drug: 12-step treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step treatment program
Study: 12823777
Drug: Antibodies (rituximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies (rituximab, alemtuzumab)
Study: 12823777
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of antibodies with chemotherapy
Study: 12823777
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies and transplantation (autologous and allogeneic)
Study: 8522226
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol at a rising dose of 2 to 8 mg, totaling 16 mg over 20 days
Study: 8522226
Drug: Intravaginal estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal estriol 0.03 mg/day for 10 days and 0.06 mg/day for 10 days
Study: 1415824
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day of alprazolam
Study: 1415824
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day of alprazolam
Study: 1415824
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day or 6 mg/day of alprazolam
Study: 3922207
Drug: Sustained-release nitroglycerin
Normalized name: nitroglycerin Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nitroglycerin
Study: 3094356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nitroglycerin and diltiazem
Study: 21378596
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily energy intake during the first week of life
Study: 16543739
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release oral morphine (SROM)
Study: 14651723
Drug: Fexofenadine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (180 mg)
Study: 7825540
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g flaxseed/d for 4 wk
Study: 7825540
Drug: Muffins containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffins containing 25 g flaxseed
Study: 26293067
Drug: 4% Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Gelofusine (GEL group)
Study: 8487823
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate 100 mg/kg/day for up to 5 days
Study: 8487823
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate 150 mg/kg/day for up to 5 days
Study: 2962623
Drug: Sufentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 15 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Study: 2962623
Drug: Sufentanil 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 7.5 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Study: 2962623
Drug: Bupivacaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Study: 27074172
Drug: Less invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less invasive surfactant administration (beractant 4 ml/kg)
Study: 27074172
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (intubation, surfactant administration, early extubation)
Study: 20718927
Drug: 300IR five-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR five-grass pollen SLIT tablets
Study: 17928199
Drug: Contrast injections
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injections (5 injections per patient)
Study: 17928199
Drug: Contrast injections
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injections (11 injections per patient)
Study: 17928199
Drug: Increasing number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing number of contrast injections
Study: 15962735
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with RF treatment (ThermaCool TC, Thermage)
Study: 15962735
Drug: No anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anesthesia with RF treatment
Study: 10384193
Drug: Antegrade pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antegrade pulmonary artery flushing with alprostadil and modified Euro‐Collins solution
Study: 8639011
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (250 mg/mo intramuscular depot injection of Sustanon)
Study: 29510234
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BT‐A) injection (200 units) into the gastrocnemius muscle
Study: 26891611
Drug: Saw Palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw Palmetto (SP) at 960 mg daily
Study: 22008269
Drug: Alcohol condition
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol condition (0.7 g pure ethanol/kg body weight)
Study: 15126001
Drug: Lipo‐PGE1 (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo‐PGE1 (10mg in 20ml of saline, injected intravenously as a bolus once daily for 2 weeks)
Study: 11669407
Drug: CHF 1035
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 1035 (10 mg/day)
Study: 7527591
Drug: Cisplatin/5-FU chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/5-FU chemotherapy
Study: 7527591
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin/5-FU) with radiotherapy
Study: 2691278
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 micrograms b.i.d.
Study: 31441407
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human high mobility group box 1 (rhHMGB1) treatment group (100 μg/L rhHMGB1)
Study: 31441407
Drug: UFH pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH pretreatment group (10 kU/L UFH + 100 μg/L rhHMGB1)
Study: 31441407
Drug: UFH control
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH control group (10 kU/L UFH)
Study: 25520366
Drug: Zinc-fortified oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-fortified oral rehydration solution (3 mg Zn)
Study: 22845710
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) pramipexole to extended-release (ER) pramipexole
Study: 22845710
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) pramipexole
Study: 11426364
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (5 g)
Study: 26453066
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin infusion controlling glycemia at 4.5‐7.2 mmol/l (Group A)
Study: 26453066
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin administered in three doses controlling glycemia at 7.2‐10.0 mmol/l (Group B)
Study: 26453066
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C) without disturbances in carbohydrate metabolism
Study: 22314814
Drug: Subcutaneous allergen-specific
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous allergen-specific immunotherapy (SCIT)
Study: 20389151
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand
Study: 20389151
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks
Study: 20389151
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand (meta-analysis)
Study: 20389151
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks (meta-analysis)
Study: 10187944
Drug: Combined steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 560 mg over 12 days)
Study: 10187944
Drug: Combined steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 715 mg over 20 days)
Study: 10187944
Drug: Combined steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined steroid therapy
Study: 7738344
Drug: Lugol's solution
Normalized name: Lugol's Solution
DrugBank: Potassium triiodide (DB14492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol's solution (approximately 170 ppm free molecular iodine)
Study: 7738344
Drug: Low-level povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-level povidone-iodine preparations (0.5-20 ppm free iodine)
Study: 7738344
Drug: Commercial povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial povidone-iodine preparation
Study: 2262896
Drug: Caffeine withdrawal
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine withdrawal (100 mg/day)
Study: 30888265
Drug: Flocculent disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flocculent disinfection (Procter and Gamble Purifier of Water [P&G PoW])
Study: 30888265
Drug: Standard SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SAM treatment protocol
Study: 24433223
Drug: diclofenac+heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac+heparin
Study: 16931507
Drug: Pramipexole 0.25
Normalized name: pramipexole 0.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.25 mg/day
Study: 16931507
Drug: Pramipexole 0.75
Normalized name: pramipexole 0.75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.75 mg/day
Study: 21063131
Drug: Pramipexole 0.25
Normalized name: pramipexole 0.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.25 mg/day (week 2)
Study: 17322624
Drug: Flecainide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 25 mg BID
Study: 17322624
Drug: Flecainide 50
Normalized name: flecainide 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 50 mg BID
Study: 17322624
Drug: Flecainide 100
Normalized name: flecainide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 100 mg BID
Study: 10563031
Drug: Methadone (33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (33% increase in daily dosage)
Study: 9832970
Drug: Zolpidem (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5, 10, and 20 mg/70 kg)
Study: 8690830
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25, and 0.50 mg/70 kg)
Study: 8690830
Drug: Temazepam (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (15, 30, and 60 mg/70 kg)
Study: 27629730
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin + 10 mg ezetimibe therapy for 6 months
Study: 27629730
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin for 6 months
Study: 21933330
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and lifestyle intervention (low glycaemic index diet and exercise programme)
Study: 7611266
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron dextran (100 mg twice weekly)